Clinical experience with an ethinyl estradiol-desogestrel oral contraceptive.
Desogestrel (150 micrograms), a potent progestogen virtually devoid of androgenic activity, was used in combination with 30 micrograms ethinyl estradiol as an oral contraceptive preparation (Marvelon). 219 women completed a total of 4074 cycles, and the use-effectiveness was 0.58 Pearl Units. Serious side effects were not observed. The drug-related discontinuation index was 12.8% in six months.
Van Trappen
Y
Y
Department of Obstetrics, University Hospital, Gent, Belgium.
Duvivier
P
P
Thiery
M
M
Van Kets
H
H
Defoort
P
P
Parewijck
W
W
Derom
R
R
Kermans
G
G
Schoofs
P
P
D000328:Adult; D000367:Age Factors; D003280:Contraceptives, Oral, Synthetic / Q000009:adverse effects; D017135:Desogestrel; D004997:Ethinyl Estradiol / Q000009:adverse effects; D005260:Female; D006801:Humans; D009652:Norpregnenes / Q000009:adverse effects; D011247:Pregnancy; D045167:Progesterone Congeners / Q000009:adverse effects; D013375:Substance Withdrawal Syndrome / Q000503:physiopathology
D003280:Contraceptives, Oral, Synthetic; D009652:Norpregnenes; D045167:Progesterone Congeners; D004997:Ethinyl Estradiol; D017135:Desogestrel